Femasys Inc. (FEMY) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Femasys Inc. on June 4, 2026. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Suwanee, Georgia. The report discloses a material corporate action regarding its capital structure.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a corporate governance event rather than financial performance.
Material Changes
The primary material change announced is a 1-for-20 reverse stock split of the Company's common stock. Key details include:
- Effective Date: The split becomes effective at 4:30 p.m. Eastern Time on June 5, 2026.
- Trading Resumption: Trading on a split-adjusted basis begins on June 8, 2026.
- Symbol and CUSIP: The stock will continue to trade under the symbol "FEMY" on The Nasdaq Stock Market LLC. The new CUSIP number is 31447E 204.
- Share Conversion: Each 20 pre-split shares will be combined into one post-split share.
- Fractional Shares: No fractional shares will be issued; they will be rounded up to the next whole share at the Depository Trust Company (DTC) participant level.
Guidance, Outlook, and Risks
The filing contains forward-looking statements subject to substantial risks and uncertainties. Management highlighted several factors that could cause actual results to differ from expectations, including:
- Ability to obtain regulatory approvals for the FemBloc product candidate.
- Success in developing, advancing, and enrolling participants in clinical trials for FemBloc.
- Demonstration of safety and effectiveness in clinical trials.
- Estimates regarding the total addressable market.
- Ability to commercialize products, including FemaSeed, and generate sales and revenues.
- Delays in commercialization and execution of strategic plans.
Investors are directed to the "Risk Factors" section of the Annual Report on Form 10-K for the year ended December 31, 2025, for a comprehensive list of risks.
Investor Verification Checklist
- Verify the new CUSIP number (31447E 204) with your brokerage to ensure proper account updates.
- Confirm the exact number of shares held post-split, noting that fractional shares are rounded up at the DTC level.
- Monitor the stock price and trading volume on June 8, 2026, when split-adjusted trading commences.
- Review the most recent Form 10-K for detailed risk factors regarding the FemBloc and FemaSeed product pipelines.
- Contact Broadridge Investor Communication Solutions at (844) 998-0339 for specific questions regarding share ownership records.